Interaction of ergot drugs with central monoamine systems. Evidence for a high potential in the treatment of mental and neurological disorders.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000378:metabolism*; D002395:Catecholamines / Q000378:metabolism*; D055598:Chemical Phenomena; D002621:Chemistry; D003342:Corpus Striatum / Q000201:enzymology; D004298:Dopamine / Q000378:metabolism; D007980:Levodopa / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008297:Male; D008711:Metergoline / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D012701:Serotonin / Q000378:metabolism
D002395:Catecholamines; D011954:Receptors, Dopamine; D008711:Metergoline; D012701:Serotonin; D007980:Levodopa; D008238:Lysergic Acid Diethylamide; D000262:Adenylyl Cyclases; D001058:Apomorphine; D004298:Dopamine; D009638:Norepinephrine